Panobinostat for treating multiple myeloma after at least 2 previous treatments - guidance (TA380)

Source:
National Institute for Health and Care Excellence - NICE
Publication date:
27 January 2016

Abstract

Evidence-based recommendations on panobinostat (Farydak) for treating multiple myeloma after at least 2 previous treatments.

Is this guidance up to date?

We reviewed the evidence in January 2019. We found nothing new that affects the recommendations in this guidance.

Next review: This guidance will be reviewed if there is new evidence that is likely to affect the recommendations.

Guidance development process

How we develop NICE technology appraisal guidance